… with advanced non–small-cell lung cancer who initiated … from EGFR TKIs, whereas the efficacy
is less certain in the patients … -, or third-line setting following cytotoxic chemotherapy were …

… as gefitinib, erlotinib, and icotinib, are the standard first-line … Lung Cancer), 3 was conducted
to compare the efficacy and … pattern of third-line therapy in patients with advanced NSCLC …

… Non-small cell lung cancer … , and the available information on treatment efficacy is relatively
sparse due to the … In the second- and third-line setting, several different therapies were used, …

… for third-line treatment of patients with metastatic colorectal … study, offers superior efficacy
compared to monotherapy, is … benefit for erlotinib users was superior, compared to gefitinib, and …

… This phase II trial evaluated the efficacy of erlotinib for patients with non‐small cell lung …
Togashi et al. have also compared gefitinib and erlotinib in terms of mean CSF concentration (8.2 …

… ) mutations in non–small-cell lung cancer predict sensitivity to … and compare the treatment
efficacy of afatinib, erlotinib, and … first-line treatment, and 10 (2.8%) received them as third-line …

… ) mutations in patients with non-small-cell lung cancer (NSCLC) is … Here, we report efficacy
and safety data from the FLAURA … 2L second line, 3L third line, EGFR epidermal growth factor …

… 85% of lung cancers are non‐small‐cell lung cancer (NSCLC… EGFR‐TKIs, such as gefitinib,
erlotinib, afatinib, dacomitinib, … receiving second‐ and third‐line osimertinib therapy. In my …

… NMA for some treatment comparisons within closed loops, namely erlotinib 150 mg, …
advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy …

… clinical use in China include gefitinib, erlotinib, and icotinib (5… Anlotinib has been recommended
as a third-line treatment for … In view of the difference in efficacy among patients in this …